Prof. Lianyu Chen 陈联誉
Chief Physician, Professor
Medical Oncology (II), Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Minimally invasive and integrated Chinese-Western medicine treatment for pancreatic, primary liver, gallbladder, and metastatic liver cancers. Procedures include biopsy, ablation (microwave, radiofrequency, cryo, drug), HIFU, arterial infusion chemotherapy/embolization, and intraperitoneal hyperthermic chemotherapy.
Dr. Chen holds a medical degree from Fudan University Shanghai Medical College and serves as Chief Physician at the Minimally Invasive Treatment Center/Integrated Chinese and Western Medicine Department, Fudan University Shanghai Cancer Center. A key member of the Liu Luming Famous TCM Studio, Dr. Chen performs over 800 minimally invasive procedures annually, leads multiple national and Shanghai research projects, has published over 10 SCI papers, and co-authored one book.
Professional roles
- Youth Committee Member, Oncology Professional Committee, Integrated Traditional Chinese and Western Medicine Branch, Chinese Medical Doctor Association
- Youth Committee Member, Tumor Minimally Invasive Treatment Committee, Shanghai Anti-Cancer Association
- Youth Committee Member, Traditional Medicine Committee, Shanghai Anti-Cancer Association
- Member, Tumor Rehabilitation Branch, China Gerontology and Geriatrics Society
Name order: in Chinese the family name comes first (Chen Lianyu). Papers usually list the name as Lianyu Chen or Chen L.
Selected publications
47 papers on PubMed matched by name and affiliation; 12 as first or senior author since 2016. Most recent first- or senior-author papers:
- Biochim Biophys Acta Rev Cancer, 2026 (senior author): Antibody-drug conjugates in treatment-resistant hepatocellular carcinoma: mechanistic insights, translational barriers, and a blueprint for salvage-line precision oncology. PubMed 42727892
- Mol Cancer, 2026 (senior author): Extracellular vesicles in solid tumors: from tumor ecology to engineered therapeutics. PubMed 42321851
- Pharmacol Res, 2025 (senior author): Hyaluronic acid and its role in pancreatic cancer: Mechanisms of tumor progression, drug resistance, and therapeutic targeting. PubMed 40972831
- Cell Biol Toxicol, 2025 (senior author): Strand-specific functions of miR-301a-3p and -5p drive opposing roles in pancreatic cancer via ferroptosis and pyroptosis. PubMed 41145839
- BMC Cancer, 2025 (senior author): Lactate-associated gene MCU promotes the proliferation, migration, and invasion of pancreatic ductal adenocarcinoma. PubMed 40399795
- Cancer Gene Ther, 2024 (senior author): Multifaceted role of microRNA-301a in human cancer: from biomarker potential to therapeutic targeting. PubMed 39317714
- Nanotechnology, 2024 (senior author): Novel silicene-mesoporous silica nanoparticles conjugated gemcitabine induced cellular apoptosis via upregulating NF-κB p65 nuclear translocation suppresses pancreatic cancer growthin vitroandin vivo. PubMed 38452386
- Cell Biosci, 2020 (senior author): Overexpression of pyruvate dehydrogenase phosphatase 1 promotes the progression of pancreatic adenocarcinoma by regulating energy-related AMPK/mTOR signaling. PubMed 32782783
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion